Ixekinumab for the treatment of ankylosing spondylitis

Jin Xian Huang,Yung Heng Lee,James Cheng-Chung Wei

Ixekinumab for the treatment of ankylosing spondylitis

2020

Jin Xian Huang
Yung Heng Lee
James Cheng-Chung Wei

Ixekinumab (IXE) is a high affinity IgG4 approved for the treatment of ankylosing spondylitis (AS). Recently, two phase III randomized clinical trials (COAST-V, COAST-W) showed significant and sust...

Keywords:

Interleukin 17
Internal medicine
Ankylosing spondylitis
Medicine
Immunology
Diabetes mellitus
Secukinumab
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations